Literature DB >> 22069060

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab is associated with a profound long-lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab-induced severe enterocolitis?

S Nancey, G Boschetti, E Cotte, K Ruel, T Almeras, M Chauvenet, K Stroeymeyt, D Moussata, D Kaiserlian, B Flourié.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22069060     DOI： 10.1002/ibd.21927

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


× No keyword cloud information.
  16 in total

1.  Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer.

Authors:  Fabian Echterdiek; Jonas Janikovits; Laura Staffa; Meike Müller; Bernd Lahrmann; Monika Frühschütz; Benjamin Hartog; Nina Nelius; Axel Benner; Mirjam Tariverdian; Magnus von Knebel Doeberitz; Niels Grabe; Matthias Kloor
Journal:  Oncoimmunology       Date:  2015-11-11       Impact factor: 8.110

Review 2.  Ubiquitin Ligases in Cancer Immunotherapy - Balancing Antitumor and Autoimmunity.

Authors:  Yu Fujita; Roberto Tinoco; Yan Li; Daniela Senft; Ze'ev A Ronai
Journal:  Trends Mol Med       Date:  2019-03-18       Impact factor: 11.951

3.  Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis.

Authors:  Andrew P Wright; Marc S Piper; Shrinivas Bishu; Ryan W Stidham
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

Review 4.  A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.

Authors:  Prabhakaran Kumar; Palash Bhattacharya; Bellur S Prabhakar
Journal:  J Autoimmun       Date:  2018-08-31       Impact factor: 7.094

Review 5.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

6.  Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Authors:  Jagpal S Klair; Mohit Girotra; Laura F Hutchins; Kari D Caradine; Farshad Aduli; Mauricio Garcia-Saenz-de-Sicilia
Journal:  Dig Dis Sci       Date:  2016-02-05       Impact factor: 3.199

Review 7.  Tipping the balance: inhibitory checkpoints in intestinal homeostasis.

Authors:  Maria E Joosse; Iris Nederlof; Lucy S K Walker; Janneke N Samsom
Journal:  Mucosal Immunol       Date:  2018-11-29       Impact factor: 7.313

8.  Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

Authors:  Jordi Rodón; Michael Carducci; Juan M Sepulveda-Sánchez; Analía Azaro; Emiliano Calvo; Joan Seoane; Irene Braña; Elisabet Sicart; Ivelina Gueorguieva; Ann Cleverly; N Sokalingum Pillay; Durisala Desaiah; Shawn T Estrem; Luis Paz-Ares; Matthias Holdhoff; Jaishri Blakeley; Michael M Lahn; Jose Baselga
Journal:  Invest New Drugs       Date:  2014-12-23       Impact factor: 3.850

9.  Infectious Colitis Associated With Ipilimumab Therapy.

Authors:  Jessica L McCutcheon; Colt M McClain; Igor Puzanov; Terrence A Smith
Journal:  Gastroenterology Res       Date:  2014-03-14

10.  EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.

Authors:  Diana I Albu; Zichun Wang; Kuan-Chun Huang; Jiayi Wu; Natalie Twine; Sarah Leacu; Christy Ingersoll; Lana Parent; Winnie Lee; Diana Liu; Renee Wright-Michaud; Namita Kumar; Galina Kuznetsov; Qian Chen; Wanjun Zheng; Kenichi Nomoto; Mary Woodall-Jappe; Xingfeng Bao
Journal:  Oncoimmunology       Date:  2017-06-28       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.